Cancer immunotherapies based on immune evasion mechanisms, which are represented by B7-H1/PD-1 pathway targeting (anti-PD therapy), have achieved higher objective response rates in patients with considerably fewer immune-related adverse events than immune enhancement, indicating that normalization cancer immunotherapy has come of age with the strenuous efforts expended to enhance clinical efficacy. Here, PDCD1 is linked to cancer.